Long-term enpatoran study for lupus skin symptoms
Part of Immune system & allergy, Skin clinical trials.
This study is a long-term follow-up of a drug called enpatoran. People who completed the earlier Elowen-1 or Elowen-2 studies can continue taking the drug to see if it keeps helping their lupus skin symptoms safely over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the full 24-week treatment in the earlier Elowen-1 or Elowen-2 studies.
- You must have active lupus skin symptoms (like rashes or lesions) at the time of joining this study.
- You must not have had a serious side effect or medical issue related to the study drug during the earlier study.
- You must not have an active serious infection (like tuberculosis) or a major infection that required hospitalization.
- You must not be taking medications that are not allowed during this follow-up study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a drug called enpatoran can help people with lupus that causes skin rashes, like discoid lupus or subacute cutaneous lupus. It may be for those with or without systemic lupus.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This study tests an investigational drug that targets a protein involved in lupus. The goal is to see if it can reduce lupus activity and improve symptoms.
This early-phase study tests a new medicine called HC022 for people with lupus (SLE) or lupus skin disease (CLE). The goal is to check its safety and see if it helps reduce symptoms, and the study will monitor you closely.
This study tests an experimental medicine called VENT-03 to see if it can improve skin lupus symptoms in adults. It compares VENT-03 against a placebo (a pill with no active drug) and includes a longer-term option where everyone can get the real drug. The goal is to find a new treatment for people whose lupus affects their skin.
This trial tests an oral drug called enpatoran for people with lupus that causes skin rashes (like discoid or subacute cutaneous lupus). The goal is to see if the drug can improve these skin symptoms.
Hear when a new Cutaneous Lupus Erythematosus (CLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.